Euclid Systems Partners With Ora, Inc. for Development of Its Novel Collagen-Based Drug Delivery System for Glaucoma Treatment

HERNDON, VA--(Marketwire - Jul 19, 2011) - Euclid Systems is pleased to announce that it has selected Ora, Inc. of Andover, MA to conduct pre-clinical and clinical development of its novel collagen-based drug delivery system for the treatment of glaucoma. This innovative product is intended to improve glaucoma patient compliance by providing sustained release of active ingredients over a period of months.

Euclid selected Ora as a development partner because of Ora's demonstrated successful track record of supporting pre-clinical and clinical study design, international regulatory strategy and execution of a broad range of ophthalmic development programs and drug delivery systems. "Ora's specific experience with the unique clinical and regulatory aspects of ophthalmic drug delivery systems makes them the ideal partner for our technology, and we look forward to collaborating with the Ora team on bringing this exciting technology into clinical development," said Dr. Bruce H. DeWoolfson, Euclid Systems, President & CEO.

Euclid's innovative technology will benefit from Ora's methodological approach to ophthalmic research. Ora's scientific and operational discipline provides products with the best chance to succeed statistically and clinically by reducing variability, and is anchored by a deep understanding of the regulatory environment.

Ora operates both a clinical research facility and a primary care ophthalmic practice as well as a large international investigator site network called OraNET. Ora's client base includes many of the most established names in ophthalmic drugs and devices as well as many smaller venture backed companies for whom they are running full turnkey development programs. In forming the new collaboration with Euclid, Ora's President and CEO, Stuart B. Abelson, stated that, "We are very excited to work with Euclid on developing their drug delivery platform, and we believe that its successful launch can greatly improve glaucoma patient compliance and validate the technology for additional indications, such as retinal disease. Technologies that improve patient compliance are a pressing unmet need within the steadily growing $6 billion worldwide glaucoma market."

About Euclid Systems: Euclid Systems Corporation is a leader in the world of eye care, providing customized acuity by developing and implementing a system of advanced vision correction, examination, design, and manufacturing technologies. These include a family of advanced GP and soft contact lenses, topographers, software, and sub-micron cutting lathes. (

About Ora: Ora, Inc. is the world's leading independent ophthalmic product development firm, with 32 FDA approvals during its 30-year history. Ora helps clients garner regulatory approvals by providing strategic clinical-regulatory guidance and complete turnkey preclinical, formulation/CMC, regulatory and clinical services. Ora's technology-based, concept-to-market services and solutions accelerate development timelines and improve the scientific quality of clinical research along every step of the development pathway. (

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.